The current earnings forecast score of aTyr Pharma Inc is 6.89, ranking 321 out of 385 in the Biotechnology & Medical Research industry. The average price target is 1.00, with a high of 20.00 and a low of 1.00.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
4.857
Target Price
+905.62%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
aTyr Pharma Inc
ATYR
9
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is aTyr Pharma Inc's price target?
Analysts forecast that aTyr Pharma Inc's price target is USD 1.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 1.00.
How have aTyr Pharma IncATYR's recent earnings per share performed?
The market expectation was USD -0.11, while aTyr Pharma IncATYR's earnings per share (EPS) for the previous quarter was USD -0.14. EPS for the next quarter is expected at USD -0.12.
What is the analyst rating for aTyr Pharma Inc?
Based on the ratings of aTyr Pharma Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.